# Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

> **NCT01243944** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 222 (actual)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** ruxolitinib tablets
- **OTHER:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT01243944
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-27
- **Primary completion:** 2014-01-15
- **Final completion:** 2018-02-09
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243944, "Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01243944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*